cART
cART is a pharmaceutical drug with 35 clinical trials. Currently 15 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 4 completed trials
Phase Distribution
Phase Distribution
13
Early Stage
10
Mid Stage
2
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
57.1%
4 of 7 finished
42.9%
3 ended early
15
trials recruiting
35
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
Targeted Therapies for Immunological Non-Responders in People With HIV: A Multicenter Clinical Study
CAR-T in Relapsed/Refractory Multiple Myeloma
Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas
A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia
CAR-T for R/R B-NHL
Clinical Trials (35)
Targeted Therapies for Immunological Non-Responders in People With HIV: A Multicenter Clinical Study
CAR-T in Relapsed/Refractory Multiple Myeloma
Radiation, Oral Vancomycin, and CAR-T for B-Cell Lymphomas
A Study of Fludarabine Dosing in Children and Young Adults With B-cell Acute Lymphoblastic Leukemia
CAR-T for R/R B-NHL
Clinical Study of XPO-1 Inhibitors Plus CAR-T Cells in Relapsed Refractory B-cell Non-Hodgkin's Lymphoma
Clinical Study on the Safety and Preliminary Efficacy of CDH17/GUCY2C CAR-T in the Treatment of Patients With Advanced Colorectal Cancer
Clinical Study on the Safety and Efficacy of CD19-BCMA CAR-T Cell Therapy for Connective Tissue Diseases
Clinical Study on the Safety and Efficacy of B7H3 CAR T Cells in Patients With B7H3 Positive Solid Tumors
Obinutuzumab, Zanubrutinib, and Lenalidomide Followed Short-Cycle of Obinutuzumab and Cytarabine in Newly Diagnosed Mantle Cell Lymphoma
Clinical Study on the Safety and Efficacy of BCMA-CART±ASCT in Treating Young Multiple Myeloma Patients
CD19 CAR-T vs DLI for Post-HSCT MRD in Ph- ALL: A RCT
Efficacy and Safety of MSLN CAR-T in Advanced Malignant Tumors
Clinical Study of Anti-CLL1-CD33-NKG2D Bicephali CAR-T for Relapsed/Refractory Acute Myeloid Leukemia
Clinical Study of CLL-1 CAR-T in the Treatment of Children With R/R AML
Predictive Factors for the Efficacy of CD19 CAR-T Therapy in Relapsed/Refractory Large B-Cell Lymphoma: A Clinical Study
To Observe the CD7-targeted CAR-T Therapy in the Treatment of r/r PTCL
CAR-T vs. Auto-SCT: Which Works Better for New Myeloma Patients?
A Study of Anti-BCMA CAR-T Therapy in Newly Diagnosed Myeloma Patients Who Are Transplant-ineligible
Comparing ASCT Followed by Anti-BCMA CAR-T vs. ASCT Alone in NDMM Patients Eligible for ASCT
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 35